TY - JOUR
T1 - Regional, circuit and network heterogeneity of brain abnormalities in psychiatric disorders
AU - Segal, Ashlea
AU - Parkes, Linden
AU - Aquino, Kevin
AU - Kia, Seyed Mostafa
AU - Wolfers, Thomas
AU - Franke, Barbara
AU - Hoogman, Martine
AU - Beckmann, Christian F.
AU - Westlye, Lars T.
AU - Andreassen, Ole A.
AU - Zalesky, Andrew
AU - Harrison, Ben J.
AU - Davey, Christopher G.
AU - Soriano-Mas, Carles
AU - Cardoner, Narcís
AU - Tiego, Jeggan
AU - Yücel, Murat
AU - Braganza, Leah
AU - Suo, Chao
AU - Berk, Michael
AU - Cotton, Sue
AU - Bellgrove, Mark A.
AU - Marquand, Andre F.
AU - Fornito, Alex
N1 - Funding Information:
K.A. is a scientific advisor to and shareholder in BrainKey Inc., a medical image analysis software company. B.F. has received educational speaking fees from Medice GmbH. C.F.B. is director and shareholder of SBGNeuro Ltd. O.A.A. is a consultant to HealthLytix and received speaker’s honorarium from Lundbeck and Sunovion. N.C. participed in advisory boards and received speaker’s honoraria from Angelini, Esteve, Janssen, Lundbeck, Novartis, Pfizer and Viatris. Furthermore, they have been awarded research grants from the Ministry of Health, Ministry of Science and Innovation (CIBERSAM), and the Strategic Plan for Research and Innovation in Health (PERIS) for the period 2016–2020, as well as from Recercaixa and Marato TV3. M.Y. has received philanthropic donations from the David Winston Turner Endowment Fund, Wilson Foundation, as well as payments in relation to court, expert witness and/or expert review reports. Finally, he has received funding to conduct sponsored Investigator-Initiated trials (including Incannex Healthcare Ltd). These funding sources had no role in the design, management, data analysis, presentation or interpretation and write-up of the data. M.Y. also sits on the Advisory Boards of Centre of The Urban Mental Health, University of Amsterdam; Enosis Therapeutics; and Monash Biomedical Imaging Centre. M.B. has received grant/research support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, Medical Benefits Fund, National Health and Medical Research Council, Medical Research Futures Fund, Beyond Blue, Rotary Health, A2 milk company, Meat and Livestock Board, Woolworths, Avant and the Harry Windsor Foundation; has been a speaker for Abbot, AstraZeneca, Janssen and Janssen, Lundbeck and Merck; and served as a consultant to Allergan, AstraZeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Eisai, Janssen and Janssen, Lundbeck Merck, Pfizer and Servier—all unrelated to this work. M.B. has received grant/research support from National Health and Medical Research Council, Wellcome Trust, Medical Research Future Fund, Victorian Medical Research Acceleration Fund, Centre for Research Excellence CRE, Victorian Government Department of Jobs, Precincts and Regions and Victorian COVID-19 Research Fund. He received honoraria from Springer, Oxford University Press, Cambridge University Press, Allen and Unwin, Lundbeck, Controversias Barcelona, Servier, Medisquire, HealthEd, ANZJP, EPA, Janssen, Medplan, Milken Institute, RANZCP, Abbott India, ASCP, Headspace and Sandoz. The other authors report no conflicts of interest.
Funding Information:
This work was supported by the MASSIVE HCP facility ( http://www.massive.org.au ). We thank B. Fulcher for helpful discussions about this manuscript, S. Oldham and S. Chopra for sharing code to generate the cortical and subcortical brain surface renderings for the figures, and M.L. Seghier for sharing code to generate threshold-weighted overlap maps. This research was supported by the following grants: US Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) K99MH127296,. L.P.; 2020 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation, L.P.; German Research Foundation (DFG; project number(s): 513851350 and 390727645), T.W.; Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) 016130669, B.F.; grant U54 EB020403 to the ENIGMA Consortium from the BD2K Initiative, a cross-NIH partnership, European College of Neuropsychopharmacology (ECNP) Network ‘ADHD Across the Lifespan’. B.F.; Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) 91619115. M.H.; Wellcome Trust (Wellcome) 215698/Z/19/Z, C.F.B.; Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organisation for Scientific Research) Vici grant no. 17854 and NWO-CAS grant no. 012-200-013. C.F.B.; Norges Forskningsråd (Research Council of Norway) 249795. L.T.W.; Norges Forskningsråd (Research Council of Norway) 298646, L.T.W.; Norges Forskningsråd (Research Council of Norway) 300767, L.T.W.; South-Eastern Norway Regional Health Authority (2018076, 2019101), L.T.W.; European Research Council (‘BRAINMINT’ 802998), L.T.W.; Norges Forskningsråd (Research Council of Norway) 223273. O.A.A.; Norges Forskningsråd (Research Council of Norway) 276082, O.A.A.; Department of Health | NHMRC 1118153. A.Z.; Department of Health | NHMRC 1064643. B.J.H.; Department of Health | NHMRC 1124472, B.J.H.; Department of Health | NHMRC 1024570. C.G.D.; Department of Health | NHMRC 1141738, C.G.D.; Generalitat de Catalunya (Government of Catalonia) SLT006/17/00249, C.S.; Carlos III Heath Institute (PI16/00889 and PI19/01171), C.S.; Secretaria d’Universitats i Recerca del Deparament d’Economia i Coneixement (2021 SGR 01017), C.S.; Secretaria d’Universitats i Recerca del Deparament d’Economia i Coneixement (2021 SGR 00832), N.C.; Carlos III Heath Institute (PI18/00036 and PI21/01756), N.C.; Turner Impact Fellowship from the Turner Institute for Brain and Mental Health. J.T.; Department of Health | NHMRC 1117188. M.Y.; Department of Health | NHMRC 1156072. M.B.; Department of Health | NHMRC 1136344. S.C.; Department of Health | NHMRC 1154378. M.A.B.; Department of Health | NHMRC 1146292, M.A.B.; Department of Health | NHMRC 1045354, M.A.B.; Department of Health | NHMRC 1006573, M.A.B.; European Research Council (ERC, grant ‘MENTALPRECISION’ 10100118), A.F.M.; Sylvia and Charles Viertel Charitable Foundation (Viertel Charitable Foundation), A.F.; Department of Health | NHMRC 1197431, A.F.; Department of Health | NHMRC 1146292, A.F.; Department of Health | NHMRC 1050504, A.F. We thank all the sites and investigators who have worked to share their data through data sharing repositories including ABIDE and OpenNeuro. This study was supported by the Australian Schizophrenia Research Bank (ASRB), which is supported by the National Health and Medical Research Council of Australia, the Pratt Foundation, Ramsay Health Care, the Viertel Charitable Foundation and the Schizophrenia Research Institute. Additional data were provided (in part) by the Human Connectome Project, WU-Minn Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. Finally, we would like to thank Nathan Spreng, Michel Thiebaut de Schotten and the anonymous reviewer who provided valuable feedback.
Publisher Copyright:
© 2023, The Author(s).
PY - 2023/9
Y1 - 2023/9
N2 - The substantial individual heterogeneity that characterizes people with mental illness is often ignored by classical case–control research, which relies on group mean comparisons. Here we present a comprehensive, multiscale characterization of the heterogeneity of gray matter volume (GMV) differences in 1,294 cases diagnosed with one of six conditions (attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, depression, obsessive–compulsive disorder and schizophrenia) and 1,465 matched controls. Normative models indicated that person-specific deviations from population expectations for regional GMV were highly heterogeneous, affecting the same area in <7% of people with the same diagnosis. However, these deviations were embedded within common functional circuits and networks in up to 56% of cases. The salience–ventral attention system was implicated transdiagnostically, with other systems selectively involved in depression, bipolar disorder, schizophrenia and attention-deficit/hyperactivity disorder. Phenotypic differences between cases assigned the same diagnosis may thus arise from the heterogeneous localization of specific regional deviations, whereas phenotypic similarities may be attributable to the dysfunction of common functional circuits and networks.
AB - The substantial individual heterogeneity that characterizes people with mental illness is often ignored by classical case–control research, which relies on group mean comparisons. Here we present a comprehensive, multiscale characterization of the heterogeneity of gray matter volume (GMV) differences in 1,294 cases diagnosed with one of six conditions (attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, depression, obsessive–compulsive disorder and schizophrenia) and 1,465 matched controls. Normative models indicated that person-specific deviations from population expectations for regional GMV were highly heterogeneous, affecting the same area in <7% of people with the same diagnosis. However, these deviations were embedded within common functional circuits and networks in up to 56% of cases. The salience–ventral attention system was implicated transdiagnostically, with other systems selectively involved in depression, bipolar disorder, schizophrenia and attention-deficit/hyperactivity disorder. Phenotypic differences between cases assigned the same diagnosis may thus arise from the heterogeneous localization of specific regional deviations, whereas phenotypic similarities may be attributable to the dysfunction of common functional circuits and networks.
UR - http://www.scopus.com/inward/record.url?scp=85168113319&partnerID=8YFLogxK
U2 - 10.1038/s41593-023-01404-6
DO - 10.1038/s41593-023-01404-6
M3 - Article
C2 - 37580620
AN - SCOPUS:85168113319
SN - 1097-6256
VL - 26
SP - 1613
EP - 1629
JO - Nature Neuroscience
JF - Nature Neuroscience
IS - 9
ER -